The leukemic risk of essential thrombocytemia;Risque leucemique des thrombocytemies

Annales de Medecine Interne

Volumn 149, Issue 2, 1998, Pages 82-86

  Liozon, Eric ^a   Turlure, Pascal ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Acute leukemia; Cytogenetics; Essential thrombocythemia; Myelodysplastic syndromes; Myelosuppressive drugs

Indexed keywords

ALKYLATING AGENT; HYDROXYUREA; ANTINEOPLASTIC AGENT;

BONE MARROW SUPPRESSION; CANCER RISK; DATA ANALYSIS; DISEASE ASSOCIATION; HUMAN; INCIDENCE; LEUKEMIA; MYELODYSPLASTIC SYNDROME; POLYCYTHEMIA VERA; PROSPECTIVE STUDY; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; BONE MARROW; CELL TRANSFORMATION; PATHOLOGY; THROMBOCYTHEMIA;

ANTINEOPLASTIC AGENTS; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LEUKEMIA; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 0032008989     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. FIALKOW PJ, FAGUET PJ, JACOBSON RJ, VAIDYA K, MURPHY S : Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood, 1981 ; 58 : 916-9.
2. EL-KASSAR N : Etude de la clonalité dans la thrombocytémie essentielle. Hématologie, 1996 ; 2 : 531-6.
3. EL-KASSAR N, HETET G, LI Y, BRIERE J, GRANDCHAMP B : Clonal analysis of haematopoietic cells in essential thrombocythemia. Br J Haematol, 1995 ; 90 : 131-7.
4. Third international workshop on chromosomes in leukemia: report on essential thrombocythemia. Cancer genet Cytogenet, 1981 ; 4 : 138-42.
5. CASE DC : Absence of a specific chromosomal marker in essential thrombocythemia. Cancer Genet Cytogenet, 1984 ; 12 : 163-5.
6. LÖFVENBERG E, NORDENSON I, WALHIN A : Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet Cytogenet, 1990 ; 49 : 57-67.
7. SESSAREGO M, DEFFERRARI R, DEJANA AM, et al. : Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genet Cytogenet, 1989 ; 43 : 57-65.
8. TURLURE P, LE PRISE PY, LETORTOREC S, et al. : Essential thrombocythemia (ET): clinical course and results of a multicenter prospective study. Blood, 1993 ; 82 (sup. 1) : 197a.
9. BELLUCCI S, JANVIER M, TOBELEM G, et al. : Essential thrombocythemias. Clinical evolutionary and biological data. Cancer, 1986 ; 58 : 2440-7.
10. HEHLMANN R, JAHN M, BAUMANN B, KÖPCKE W : Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer, 1988 ; 61 : 2487-96.
11. FENAUX P, SIMON M, CAULIER MT, LAI JL, GOUDEMAND J, BAUTERS F : Clinical course of essential thrombocythemia in 147 cases. Cancer, 1990 ; 66 : 549-56.
12. COLOMBI M, RADAELLI F, ZOCCHI L, MAIOLO AT : Thrombotic and hemorragic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer, 1991 ; 67 : 2926-30.
13. LIOZON E, BRIGAUDEAU C, TRIMOREAU F, et al. : Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther, 1997 ; 39 : 11-8.
14. MURPHY S, ILAND H, ROSENTHAL D, LASZLO J : Essential thrombocythemia: an interim report from the polycythemia vera study group. Semin Hematol, 1986 ; 23 : 177-82.
15. CERVANTES F, URBANO-ISPIZUA A, FELIU E, et al. : Ph-positive chronic myeloid leukemia mimicking essential thrombocythemia and terminating into megakaryoblastic crisis: report of two cases with molecular studies. Leukemia, 1993 ; 7 : 327-30.
16. WEINFELD A, SWOLIN B, WESTIN J : Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacity and leukaemogenicity with therapeutic implications. Eur J Haematol, 1994 ; 52 : 134-9.
17. PETERSON P, MURPHY S, ILAND HJ, GELLER SA, ELLIS JT : Occurence of acute leukemia in treated essential thrombocythemia. Lab Invest, 1994 ; 70 : 118-A.
18. HIGUCHI T, OKADA S, MORI H, NIIKURA H, OMINE M, TERADA H : Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer, 1995 ; 75 : 471-7.
19. SEDLACEK SM, CURTIS JL, WEINTRAUB J, LEVIN J : Essential thrombocythemia and leukemic transformation. Medicine. 1986 ; 65 : 353-64.
20. RAMAN SBK, MAHMOOD A, VAN SLYCK EJ, SAEED SM : Essential thrombocythemia with transition into acute leukemia. Ann NY Acad Sci, 1981 ; 370 : 145-53.
21. GELLER SA, SHAPIRO E : Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol, 1982 ; 77 : 353-6.
22. NERI A, FRACCHIOLLA NS, RADAELLI F, et al. : p53 tumour suppressor gene and RAS oncogenes: molecular analysis in the chronic and leukemic phases of essential thrombocythaemia. British J Haematol, 1996 ; 93 : 670-3.
23. CORTELAZZO S, FINAZZI G, RUGGERI M, et al. : Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med, 1995 ; 332 : 1132-6.
24. FREI-LAHR D, BARTON JC, HOFFMAN R, BURKETT LL, PRCHAL JT : Elastic transformation of essential thrombocythemia: dual expression of myelomonoblastic/megakaryoblastic phenotypes. Blood, 1984 ; 63 : 866-72.
25. KIMURA A, FUJIMOTO T, INADA T, et al. : Blastic transformation in essential thrombocythemia. In vitro differentiation of blast cells into granulocytic, erythroid, and megakaryocytic lineages. Cancer, 1990 ; 65 : 1538-44.
26. EMILIA G, SACCHI S, TEMPERANI P, LONGO R, VECCHI A : Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Leuk Lymphoma, 1993 ; 9 : 423-6.
27. ASANO Y, NARITOMI Y, KIMURA H, et al. : Low-dose aclarubicin in blastic transformation of essential thrombocythemia. Ann Hematol, 1991 ; 162 : 194-5.
28. MURPHY PT, SIVAKUMARAN M, VAN RHEE F, WATMORE AE, MITCHELL VE : Acute lymphoblastic transformation of essential thrombocythemia. Br J Haematol, 1995 ; 89 : 921-2.
29. MITUS AJ, BARBUI T, SHULMAN LN, et al. : Hemostatic complications in young patients with essential thrombocythemia. Am J Med, 1990 ; 88 : 371-5.
30. ROZMAN C, GIRALT M, FELIU E, RUBIO D, CORTES MT : Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer, 1991 ; 67: 2658-63.
31. BOIVIN P : Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv Rev fr Hematol, 1993 ; 35 : 491-8.
32. LÖFVENBERG E, WAHLIN A : Management of polycythemia vera, essential thrombocythemia and myelofibrosis with hydroxyurea. Eur J Haematol, 1988 ; 41 : 375-81.
33. CASSIATO DA, SCOTT JL : Acute leukemia following prolonged cytotoxic agent therapy. Medicine, 1979 ; 58 : 32-46.
34. LE BEAU MM, ALBAIN KS, LARSON RA, et al. : Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol, 1986 ; 4: 325-45.
35. FRUCHTMAN SM, KAPLAN ME, PETERSON P, MACK K, BERK PD, WASSERMAN LR : Acute leukemia, hydroxyurea and polycythemia vera: an analysis of risk from the polycythemia vera study group (PVSG). Blood, 1994 ; 84 (Suppl. 1) : 518a.
36. BRANDT L, ANDERSON H : Survival and risk of leukaemia in polycythemia vera and essential thrombocythemia treated with oral radiophosphorus: are safer drugs available? Eur J Haematol, 1995 ; 54 : 21-6.
37. NAND S, STOCK W, GODWIN J, FISHER S : Leukemogenic risk of hydroxyurea (HU) therapy in polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM). Blood, 1995 ; 86 (Suppl. 1) : 798a.
38. KWONG YL : leukaemic risk in polycythaemia vera and essential thrombocythaemia. Eur J Haematol, 1996 ; 56 : 90-2.
39. CERVANTES F, TASSIES D, SALGADO C, ROVIRA M, PEREIRA A, ROZMAN C : Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol, 1991 ; 85 : 124-7.
40. STERKERS Y, PREUDHOMME C, LAÏ JL, et al. : Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocytemia treated with hydroxyurea : high proportion of cases with 17p deletion. Blood, 1998 ; 91 : 616-22.
41. PEARSON TC : Primary thrombocythemia: diagnosis and management. Br J Haematol, 1991 ; 78 : 145-8.